{"gao_id": "GAO-22-103611", "published": "2022-01-07T12:00:00Z", "released": "2022-02-07T07:00:00Z", "summary": "The Food and Drug Administration inspects foreign and domestic drug manufacturers to ensure drug safety and effectiveness. More than 50% of manufacturers supplying the U.S. market are located overseas\u2014many in India and China. The pandemic postponed almost all foreign inspections for most of 2020. But the number of these inspections had generally been declining since FY 2016\u2014which FDA attributes in part to fewer investigators. We...", "title": "Drug Safety: FDA Should Take Additional Steps to Improve Its Foreign Inspection Program", "topics": ["Generic drugs", "Manufacturing", "Health care", "pandemics", "Compliance oversight", "Drugs", "Foreign drug inspection", "Prescription drugs", "Drug safety", "Active pharmaceutical ingredient", "Health Care"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-22-103611", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-22-103611-highlights.pdf"}, {"title": "Full Report (67 pages)", "url": "https://www.gao.gov/assets/gao-22-103611.pdf"}, {"title": "Accessible PDF (77 pages)", "url": "https://www.gao.gov/assets/720/718363.pdf"}]}